Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-5996
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis ; volume:7 ; number:1 ; day:17 ; month:5 ; year:2015 ; pages:1-6 ; date:12.2015
Diabetology & metabolic syndrome ; 7, Heft 1 (17.5.2015), 1-6, 12.2015
- Urheber
-
Terawaki, Yuichi
Nomiyama, Takashi
Takahashi, Hiroyuki
Tsutsumi, Yoko
Murase, Kunitaka
Nagaishi, Ryoko
Tanabe, Makito
Kudo, Tadachika
Kobayashi, Kunihisa
Yasuno, Tetsuhiko
Nakashima, Hitoshi
Yanase, Toshihiko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13098-015-0043-2
- URN
-
urn:nbn:de:101:1-2021081506493570806644
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Terawaki, Yuichi
- Nomiyama, Takashi
- Takahashi, Hiroyuki
- Tsutsumi, Yoko
- Murase, Kunitaka
- Nagaishi, Ryoko
- Tanabe, Makito
- Kudo, Tadachika
- Kobayashi, Kunihisa
- Yasuno, Tetsuhiko
- Nakashima, Hitoshi
- Yanase, Toshihiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
Renal effects of the dipeptidyl peptidase inhibitor linagliptin in non-diabetic rats with 5/6 nephrectomy
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
Dipeptidyl peptidase IV : general and applied aspects
Dipeptidyl-Peptidase IV : Biochemie, Physiologie u. Pathobiochemie
Angioedema associated with dipeptidyl peptidase-IV inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
Beiträge zur kinetischen Charakterisierung der Dipeptidyl-Peptidase IV
Development of dipeptidyl peptidase 8 and 9 inhibitors
Population pharmacokinetic and pharmacodynamic modelling and simulation of linagliptin, a novel dipeptidyl-peptidase 4 inhibitor for the treatment of type 2 diabetes
Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation of Linagliptin, a Novel Dipeptidyl-Peptidase 4 Inhibitor for the Treatment of Type 2 Diabetes
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
Renal effects of the dipeptidyl peptidase inhibitor linagliptin in non-diabetic rats with 5/6 nephrectomy
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
Dipeptidyl peptidase IV : general and applied aspects
Dipeptidyl-Peptidase IV : Biochemie, Physiologie u. Pathobiochemie
Angioedema associated with dipeptidyl peptidase-IV inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
Beiträge zur kinetischen Charakterisierung der Dipeptidyl-Peptidase IV
Development of dipeptidyl peptidase 8 and 9 inhibitors
Population pharmacokinetic and pharmacodynamic modelling and simulation of linagliptin, a novel dipeptidyl-peptidase 4 inhibitor for the treatment of type 2 diabetes
Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation of Linagliptin, a Novel Dipeptidyl-Peptidase 4 Inhibitor for the Treatment of Type 2 Diabetes
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
Renal effects of the dipeptidyl peptidase inhibitor linagliptin in non-diabetic rats with 5/6 nephrectomy
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
Dipeptidyl peptidase IV : general and applied aspects
Dipeptidyl-Peptidase IV : Biochemie, Physiologie u. Pathobiochemie
Angioedema associated with dipeptidyl peptidase-IV inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
Beiträge zur kinetischen Charakterisierung der Dipeptidyl-Peptidase IV
Development of dipeptidyl peptidase 8 and 9 inhibitors
Population pharmacokinetic and pharmacodynamic modelling and simulation of linagliptin, a novel dipeptidyl-peptidase 4 inhibitor for the treatment of type 2 diabetes